MAPT and Alzheimer disease: Interestingly, as tau and amyloid are common co-pathologies in PD, the same is true for a-synuclein as a co-pathology in AD, where it was found in >50% of cases at autopsy and shown to exacerbate cerebral glucose hypometabolism, cognitive impairment and rate of decline in AD patients [16].